· Published by Health Canada · Official notice
This is duplicated text of a letter from EMD Serono Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
December 22, 2008
Subject: Association of RAPTIVA® (efalizumab) with Serious Infections, including Progressive Multifocal Leukoencephalopathy
Dear Health Care Professional,
EMD Serono Canada Inc., in collaboration with Health Canada, would like to inform you of important new safety information regarding the risk of serious infections, including progressive multifocal leukoencephalopathy (PML), in patients receiving RAPTIVA® (efalizumab).
RAPTIVA is an immunomodulating, humanized monoclonal antibody and is currently authorized for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is estimated that approximately 46,000 patients have been administered RAPTIVA worldwide, since this drug was first authorized.
Infections, some serious and leading to hospitalizations or deaths, have been observed in patients treated with RAPTIVA. These infections have included bacterial sepsis, viral meningitis, shingles, invasive fungal disease, John Cunningham (JC) virus infection leading to PML, and other opportunistic infections.
PML is a rare, progressive, demyelinating disease of the central nervous system that can lead to death or severe disability. PML is caused by reactivation of the (JC) virus, which usually resides and stays dormant in latent form in up to 80% of healthy adults. The JC virus typically only causes PML in immune compromised patients. The factors leading to activation of the latent infection are not fully understood, although abnormalities in T cells have been described as important for viral reactivation.
There have been reported cases of PML associated with other systemic therapies used for psoriasis, although the affected patients were being treated for conditions other than psoriasis. PML has also been observed in HIV positive patients, immune suppressed cancer patients, transplantation patients and patients with autoimmune diseases.
There have been two reports in the United States, of JC virus infection with resultant PML and death in patients who had been treated with RAPTIVA for plaque psoriasis. Both of these patients had longstanding psoriasis and one of them had received a total of two short courses of another immunosuppressive drug, before and during RAPTIVA therapy. Both these patients were diagnosed with PML approximately 4 years after continuous treatment with RAPTIVA. In both cases, PML was diagnosed based on the detection of JC viral DNA in the cerebro-spinal fluid, clinical symptoms, and magnetic resonance imaging (MRI) findings. There are no other cases of confirmed PML in RAPTIVA treated patients in the worldwide safety database.
EMD Serono Canada was also informed of a fatal case of suspected PML in a patient with chronic plaque psoriasis who developed progressive degenerative neurologic symptoms, after being treated with RAPTIVA for longer than 3 years. However, a final diagnosis was not made and PML was not confirmed in that patient.
There are no known interventions that can reliably prevent or adequately treat PML.
As a result:
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any occurrence of serious and/or unexpected adverse reactions in patients receiving RAPTIVA should be reported to EMD Serono Canada Inc., or Health Canada at the following addresses:
EMD Serono Canada Inc.,
2695 North Sheridan Way, Suite 200
Mississauga ON L5K 2N6
Tel: 1-888-737-6668 ext. 5160
Fax: 905-919-0292
E-mail: drugsafetycanada@merckserono.net
Any suspected adverse reaction can also be reported to:
Canada Vigilance Program
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Telephone: 613-957-0337 or Fax: 613-957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Telephone: 866-234-2345
Fax: 866-678-6789
CanadaVigilance@hc-sc.gc.ca
The Adverse Reaction Reporting Form and the Adverse Reaction Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: MHPD_DPSC@hc-sc.gc.ca
Tel: 613-954-6522
Fax: 613-952-7738
Should you have any questions regarding the use of RAPTIVA, please call the EMD Serono Medical Information/Drug Safety Department at 1-888-737-6668 x5160.
original signed by
Dr. Horia Ijacu
Medical Director, Marketed Products
EMD Serono Canada